REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
REGENXBIO Inc. (Nasdaq: RGNX) has announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on Thursday, August 15, 2024. The company will be part of a panel discussion titled 'The Evolving Therapeutic Landscape of AMD' scheduled for 9:00 a.m. EDT.
Interested parties can access a live webcast of the panel through the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay will be available for approximately 30 days following the presentation, providing an opportunity for those unable to attend the live event to catch up on the discussion.
REGENXBIO Inc. (Nasdaq: RGNX) ha annunciato la sua partecipazione alla 4ª Conferenza Virtuale Annuale di Oftalmologia H.C. Wainwright che si terrà giovedì 15 agosto 2024. L'azienda prenderà parte a una tavola rotonda dal titolo 'Il Paesaggio Terapeutico in Evoluzione dell'AMD' programmata per le 9:00 a.m. EDT.
Le parti interessate possono accedere a una webcasting dal vivo del panel attraverso la sezione Investitori del sito web di REGENXBIO all'indirizzo www.regenxbio.com. Una registrazione archiviata sarà disponibile per circa 30 giorni dopo la presentazione, offrendo l'opportunità a coloro che non possono partecipare all'evento dal vivo di recuperare la discussione.
REGENXBIO Inc. (Nasdaq: RGNX) ha anunciado su participación en la 4ª Conferencia Virtual Anual de Oftalmología de H.C. Wainwright el jueves 15 de agosto de 2024. La compañía será parte de un panel titulado 'El Panorama Terapéutico Evolutivo de la AMD' programado para las 9:00 a.m. EDT.
Las partes interesadas pueden acceder a una transmisión en vivo del panel a través de la sección de Inversores del sitio web de REGENXBIO en www.regenxbio.com. Una repetición archivada estará disponible durante aproximadamente 30 días después de la presentación, proporcionando una oportunidad para aquellos que no pueden asistir al evento en vivo de ponerse al día con la discusión.
REGENXBIO Inc. (Nasdaq: RGNX)는 H.C. Wainwright 제4회 연례 안과 가상 회의에 2024년 8월 15일 목요일 참가한다고 발표했습니다. 이 회사는 'AMD의 진화하는 치료 환경'이라는 제목의 패널 토론에 오전 9:00 EDT에 참여할 예정입니다.
관심 있는 당사자는 REGENXBIO 웹사이트의 투자자 섹션을 통해 패널 생중계에 접속할 수 있습니다. 발표 후 약 30일 동안 아카이브된 재생본이 제공되어, 라이브 이벤트에 참석할 수 없는 분들이 토론 내용을 확인할 수 있는 기회를 제공합니다.
REGENXBIO Inc. (Nasdaq: RGNX) a annoncé sa participation à la 4ème Conférence Virtuelle Annuelle d'Ophthalmologie H.C. Wainwright prévue pour le jeudi 15 août 2024. L'entreprise prendra part à une discussion en panel intitulée 'Le Paysage Thérapeutique en Évolution de la DMLA' prévue à 9h00 EDT.
Les parties intéressées peuvent accéder à une diffusion en direct du panel via la section Investisseurs du site web de REGENXBIO à l'adresse www.regenxbio.com. Une rediffusion archivée sera disponible pendant environ 30 jours après la présentation, offrant ainsi une opportunité à ceux qui ne peuvent pas assister à l'événement en direct de se tenir au courant de la discussion.
REGENXBIO Inc. (Nasdaq: RGNX) hat seine Teilnahme an der 4. Jährlichen Virtuellen Augenheilkunde-Konferenz von H.C. Wainwright am Donnerstag, den 15. August 2024 angekündigt. Das Unternehmen wird an einer Paneldiskussion mit dem Titel 'Die sich entwickelnde therapeutische Landschaft der AMD' teilnehmen, die für 9:00 Uhr EDT geplant ist.
Interessierte Parteien können über den Bereich Investoren auf der Website von REGENXBIO unter www.regenxbio.com auf einen Live-Stream des Panels zugreifen. Eine archivierte Wiederholung wird etwa 30 Tage nach der Präsentation verfügbar sein, sodass diejenigen, die nicht an der Live-Veranstaltung teilnehmen können, die Diskussion nachverfolgen können.
- None.
- None.
H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Panel: The Evolving Therapeutic Landscape of AMD
Date/Time: Thursday, August 15, 2024 at 9:00 a.m. EDT
Location: Virtual
A live webcast of the panel can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.
ABOUT REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA® for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.regenxbio.com.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-the-hc-wainwright-4th-annual-ophthalmology-virtual-conference-302217608.html
SOURCE REGENXBIO Inc.
FAQ
When is REGENXBIO (RGNX) participating in the H.C. Wainwright Ophthalmology Conference?
What panel is REGENXBIO (RGNX) participating in at the 2024 H.C. Wainwright conference?
What time is REGENXBIO's (RGNX) panel at the H.C. Wainwright conference on August 15, 2024?
How can I watch REGENXBIO's (RGNX) panel at the 2024 H.C. Wainwright Ophthalmology Conference?
How long will the replay of REGENXBIO's (RGNX) panel be available after the August 15, 2024 conference?
